Life Sciences – Weekly Industry News

(BW) Teva and Mylan Settle Copaxone(R) Patent Litigation in France, the UK and the Netherlands, Posted on The Wall Street Journal

JERUSALEM–(BUSINESS WIRE)–November 25, 2013–  Teva Pharmaceutical Industries (NYSE:TEVA) and Mylan Inc. (NASDAQ:MYL) today announce that certain of their affiliates have agreed to settle and dismiss pending patent litigation involving Copaxone(R) (glatiramer acetate) in the United Kingdom, the Netherlands and France relating to non-infringement and the validity of European Patent 0,762,888, which expires in May 2015. The terms of the settlement are confidential. [Read More…]  

A Myriad of Tips on Biotech Patent Prosecution, By Dolly J. Krishnaswamy, Posted on IPWatchDog

“It’s never good news when your area of the law is on 60 minutes,” says Courtenay Brinckerhoff, partner at Foley & Lardner LLP at the 2013 AIPLA Annual Meeting. It’s no secret that the Association for Molecular Pathology v. Myriad Genetics case had more than its fair share of media buzz. The decision, holding that isolated DNA was not patent eligible, left many of us wondering how to best address the needs of our biotech clients going forward. [Read More…]  

Invitae Responds to Myriad Genetics Lawsuit, Posted on 4-traders

Invitae Corporation, a genetic diagnostics company, today announced that it plans to defend its right to provide naturally occurring genetic information and services to physicians for their cancer patients through its genetic testing services. Invitae has been named a defendant in a lawsuit filed by Myriad Genetics, Inc. regarding Invitae’s BRCA and MUTYH genetic tests. Invitae disagrees with the allegations of the lawsuit and plans to vigorously defend itself against the lawsuit, which it believes has no merit. [Read More…]  

Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) – Global Forecast to 2018, Posted on The Sacramento Bee

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Calcitonin and glucagon are considered in the recombinant peptides market. [Read More…]  

Biocon, Mylam get approval for biosimilar of cancer drug Herceptin, By C.H. Unnikrishnan, Posted on Live Mint

Mumbai: Biocon Ltd said on Tuesday that the Drugs Controller General of India (DCGI) has given it permission to sell a biological copy of Herceptin, the world’s best-selling breast cancer drug. The biosimilar trastuzumab, a biological copy of Herceptin, was developed jointly by Biocon and US generic drug maker Mylan Inc., and will be sold in India under the brand name Canmab, Biocon said in a statement on Tuesday. It will be available in India by the fourth quarter of fiscal year 2014. [Read More…]

Live Industry News



Follow @C5Live     LinkedIn-Logo-2C (1) Join Life Science & Healthcare Experts: Networking Group    

Related Events

Anti Corruption Pharmaceutical and Medical Devices IndustryBiosimilars25th Biotech PatentingPharma & Biotech Patent Litigation   For a complete list of all Life Sciences upcoming events: Click Here